Efficacy and safety of perampanel for the treatment of epilepsy in adolescents: a meta-analysis

References

• Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the international league against epilepsy (ILAE) and the international bureau for epilepsy (IBE). Epilepsia. 2005;46(4):470–472.
   PubMed Web of Science ®Google Scholar
• Tellez-Zenteno JF, Dhar R, Wiebe S. Long-term seizure outcomes following epilepsy surgery: a systematic review and meta-analysis. Brain. 2005; 128(Pt 5):1188–1198.
   PubMedGoogle Scholar
• Camfield P, Camfield C. Incidence, prevalence and aetiology of seizures and epilepsy in children. Epileptic Disord. 2015; 17(2):117–123.
   PubMed Web of Science ®Google Scholar
• Brodie MJ. Antiepileptic drug therapy the story so far. Seizure. 2010; 19(10):650–655.
   PubMed Web of Science ®Google Scholar
• Tsai JJ, Wu T, Leung H, et al. Dash AJANS: perampanel, an AMPA receptor antagonist: from clinical research to practice in clinical settings. Acta Neurol Scand. 2018; 137(4):378–391.
   PubMed Web of Science ®Google Scholar
• Plosker GL. Perampanel: as adjunctive therapy in patients with partial-onset seizures. CNS Drugs. 2012; 26(12):1085–1096.
   PubMed Web of Science ®Google Scholar
• Hanada T, Hashizume Y, Tokuhara N, et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011; 52(7):1331–1340.
   PubMed Web of Science ®Google Scholar
• French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013; 54(1):117–125.
   PubMed Web of Science ®Google Scholar
• Kramer LD, Satlin A, Krauss GL, et al. Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies. Epilepsia. 2014; 55(3):423–431.
   PubMed Web of Science ®Google Scholar
• Garza P, Rosenfeld W, Saeki K, et al. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies. Epilepsy Behav. 2020; 104:106876.
   PubMed Web of Science ®Google Scholar
• Lagae L, Villanueva V, Meador KJ, et al. Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: a randomized study evaluating behavior, efficacy, and safety. Epilepsia. 2016; 57(7):1120–1129.
   PubMed Web of Science ®Google Scholar
• Rosenfeld W, Conry J, Lagae L, et al. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study. Eur J Paediatr Neurol. 2015; 19(4):435–445.
   PubMed Web of Science ®Google Scholar
• Meador KJ, Yang H, Pina-Garza JE, et al. Cognitive effects of adjunctive perampanel for partial-onset seizures: a randomized trial. Epilepsia. 2016; 57(2):243–251.
   PubMed Web of Science ®Google Scholar
• Pina-Garza JE, Lagae L, Villanueva V, et al. Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures. Epilepsy Behav. 2018; 83:50–58.
   PubMed Web of Science ®Google Scholar
• Yun Y, Kim D, Lee YJ, et al. Efficacy and tolerability of adjunctive perampanel treatment in children under 12 years of age with refractory epilepsy. Korean J Pediatr. 2019; 62(7):269–273.
   PubMedGoogle Scholar
• De Liso P, Vigevano F, Specchio N, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-An italian observational multicenter study. Epilepsy Research. 2016; 127:93–100.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Prisma group T: Ítems de referencia Para publicar revisiones sistemáticas y metaanálisis: La declaración PRISMA. Rev Esp Nutr Hum Diet. 2014; 18(3):172.
   Google Scholar
• Higgins JP, Altman DG, Gotzsche PC, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928:
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177–188.
   PubMedGoogle Scholar
• Dorans NJ, Holland PW. Dif detection and description: Mantel-Haenszel and Standardization1,2. ETS Res Rep Series. 1992; 1992(1):i–40.
   Google Scholar
• Peters JL, Sutton AJ, Jones DR, et al. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006; 295(6):676–680.
   PubMed Web of Science ®Google Scholar
• Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006; 25(20):3443–3457.
   PubMed Web of Science ®Google Scholar
• Chang FM, Fan PC, Weng WC, et al. The efficacy of perampanel in young children with drug-resistant epilepsy. Seizure. 2020; 75:82–86.
   PubMed Web of Science ®Google Scholar
• Heyman E, Lahat E, Levin N, et al. Tolerability and efficacy of perampanel in children with refractory epilepsy. Dev Med Child Neurol. 2017; 59(4):441–444.
   PubMed Web of Science ®Google Scholar
• Biro A, Stephani U, Tarallo T, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences. Neuropediatrics. 2015; 46(2):110–116.
   PubMed Web of Science ®Google Scholar
• Kossoff EH. Intractable childhood epilepsy: choosing between the treatments. Semin Pediatr Neurol. 2011; 18(3):145–149.
   PubMed Web of Science ®Google Scholar
• Verrotti A, Loiacono G, Coppola G, et al. Pharmacotherapy for children and adolescents with epilepsy. Expert Opin Pharmacother. 2011; 12(2):175–194.
   PubMed Web of Science ®Google Scholar
• French JA, Staley BA. AED treatment through different ages: as our brains change, should our drug choices also? Epilepsy Curr. 2012; 12(Suppl 3):22–27.
   PubMedGoogle Scholar
• Nordli DR. Special needs of the adolescent with epilepsy. Epilepsia. 2004; 42:10–17.
   Google Scholar
• Wu GK, He Y. Meta-analysis of efficacy and safety of perampanel in treatment of refractory partial-onset seizures. Drug Evaluat Res. 2017; 40(8):1157–1162.
   Google Scholar